Avalyn Pharma (NASDAQ:AVLN) Shares Down 8.1% – Time to Sell?

by · The Cerbat Gem

Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report)’s share price fell 8.1% on Monday . The stock traded as low as $26.01 and last traded at $26.45. 51,037 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 346,334 shares. The stock had previously closed at $28.78.

Analyst Ratings Changes

Several research firms have recently weighed in on AVLN. Guggenheim began coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley began coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price target on the stock. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Finally, Evercore began coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $59.00.

Get Our Latest Research Report on Avalyn Pharma

Avalyn Pharma Trading Down 7.2%

Insider Buying and Selling at Avalyn Pharma

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jill Carroll bought 277,778 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 14.55% increase in their position. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

(Get Free Report)

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

Featured Articles